JECHO (Jecho Biopharmaceuticals Co., Ltd.) and Jecho Labs are collaborating with Shanghai Jiao Tong University, People’s Hospital of Henan Province, and Wuhan Virology Institute (Chinese Academy of Sciences) on developing therapeutic neutralizing antibody against COVID-19.

Using our established and fully human scFv phage display library, we will screen antibodies with high affinity to S1 and S2 domains of the spike protein and evaluate their in vitro cell neutralizing potency through the cell based model system established in the lab. GMP production will be conducted by Jecho Biopharm to support clinical studies to serve the current urgent needs from the patients.

Project Update March 23rd

Using our established fully human scFv phage display library, we have isolated dozens of monoclonal antibodies recognizing specifically the receptor binding domain (RBD) of the SARS-C0V-2 spike protein and are evaluating their in vitro virus neutralizing potency through the cell based model system established in the lab. GMP production will be conducted by Jecho Biopharm to support clinical studies to serve the current urgent needs from the patients.

Source from Jecholabs.com